We catch up with our US Editor-in-Chief to discuss advances in molecular targets and treatment in multiple myeloma, as well as important updates in the latest NCCN guidelines.
1. What do you consider the most important unmet needs in the treatment of multiple myeloma? (0:11)
2. What are the most important emerging molecular targets in the treatment of multiple myeloma? (1:14)
3. What new treatment approaches do you expect to emerge in coming years? (3:51)
4. What therapies have become available for patients with relapsed/refractory disease? (4:32)
5. What are the most important updates and changes in the latest NCCN Guidelines for multiple myeloma? (5:33)
Speaker disclosures: Shaji Kumar has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
